产品封面图
文献支持

MDA-MB-435S细胞

收藏
  • ¥1320
  • BHcell(博辉生物)
  • BH-C344
  • 2026年01月19日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    MDA-MB-435S/MDA-MB-435S细胞系/MDA-MB-435S细胞株/MDA-MB-435S人乳腺导管癌细胞

    Cell line name MDA-MB-435S

    Synonyms MDA-MB-435s; MDA-MB-435 S; MDA-MB-435-S; MDAMB435S; BrCL15

    Accession CVCL_0622

    Resource Identification Initiative To cite this cell line use: MDA-MB-435S (RRID:CVCL_0622)

    Comments Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.

    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: KuDOS 95 cell line panel.

    Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.

    Population: Caucasian.

    Microsatellite instability: Stable (MSS) (PubMed=12661003).

    Omics: Array-based CGH.

    Omics: Deep exome analysis.

    Omics: miRNA expression profiling.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.

    Sequence variations

    Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=19593635; DepMap=ACH-000884).

    Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19593635).

    Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=19593635).

    Mutation; HGNC; 3373; EP300; Simple; p.Leu827Pro (c.2480T>C); Zygosity=Hemizygous (PubMed=10700188).

    Mutation; HGNC; 3373; EP300; Simple; p.Glu1013Gly (c.3038A>G); ClinVar=VCV000562024; Zygosity=Hemizygous (PubMed=10700188).

    Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=16541312; DepMap=ACH-000884).

    HLA typing Source: PubMed=26589293

    Class I

    HLA-A A*24:02,24:02

    HLA-B B*15:01,15:01

    HLA-C C*03:03,03:03

    Genome ancestry Source: PubMed=30894373

     

    Origin % genome

    African 0.01

    Native American 0

    East Asian, North 2.13

    East Asian, South 0

    South Asian 0

    European, North 65.23

    European, South 32.63

    Disease Amelanotic melanoma (NCIt: C3802)

    Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

    Hierarchy Parent: CVCL_0417 (MDA-MB-435)

    Children:

    CVCL_A6LJ (MDA-MB-435S/1) CVCL_5T70 (MDA-MB-435s-mKate2)

    Sex of cell Male

    Age at sampling 33Y

    Category Cancer cell line

    STR profile Source(s): ATCC=HTB-129; CCRID; CLS=300277; PubMed=28940260

     

    Markers:

    Amelogenin X

    CSF1PO 11 (ATCC=HTB-129; CCRID; CLS=300277)

    11,12 (PubMed=28940260)

    D1S1656 12

    D2S1338 19,24

    D3S1358 14 (ATCC=HTB-129; CLS=300277; PubMed=28940260)

    14,20 (CCRID)

    D5S818 11,12 (CCRID)

    12 (ATCC=HTB-129; CLS=300277; PubMed=28940260)

    D6S1043 11

    D7S820 8 (PubMed=28940260)

    8,10 (ATCC=HTB-129; CCRID; CLS=300277)

    D8S1179 13 (ATCC=HTB-129; CCRID; CLS=300277)

    13,14 (PubMed=28940260)

    D12S391 18,19

    D13S317 12 (ATCC=HTB-129; CCRID; PubMed=28940260)

    12,13 (CLS=300277)

    D16S539 13

    D18S51 13 (ATCC=HTB-129; PubMed=28940260)

    13,17 (CLS=300277)

    D19S433 14 (CCRID)

    14,15 (ATCC=HTB-129; CLS=300277; PubMed=28940260)

    D21S11 30

    FGA 21

    Penta D 9,11

    Penta E 10,12

    TH01 6,7

    TPOX 8,11

    vWA 16,18

     

    PubMed=2007622; DOI=10.1083/jcb.113.1.173; PMCID=PMC2288921

    Frixen U.H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., Lochner D., Birchmeier W.

    E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.

    J. Cell Biol. 113:173-185(1991)

     

    DOI=10.1016/B978-0-12-333530-2.50009-5

    Leibovitz A.

    Cell lines from human breast.

    (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)

     

    PubMed=10700188; DOI=10.1038/73536

    Gayther S.A., Batley S.J., Linger L., Bannister A.J., Thorpe K., Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.

    Mutations truncating the EP300 acetylase in human cancers.

    Nat. Genet. 24:300-303(2000)

     

    PubMed=12354931; DOI=10.1136/mp.55.5.294; PMCID=PMC1187258

    Ellison G., Klinowska T., Westwood R.F.R., Docter E., French T., Fox J.C.

    Further evidence to support the melanocytic origin of MDA-MB-435.

    Mol. Pathol. 55:294-299(2002)

     

    PubMed=12661003; DOI=10.1002/gcc.10196

    Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

    Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

    Genes Chromosomes Cancer 37:29-35(2003)

     

    PubMed=15677628; DOI=10.1093/carcin/bgi032

    Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.

    Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

    Carcinogenesis 26:923-930(2005)

     

    PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853

    Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

    BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

    Cancer Res. 66:41-45(2006)

     

    PubMed=16541312; DOI=10.1007/s10549-006-9186-z

    Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

    Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

    Breast Cancer Res. Treat. 99:97-101(2006)

     

    PubMed=19593635; DOI=10.1007/s10549-009-0460-8

    Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

    Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

    Breast Cancer Res. Treat. 121:53-64(2010)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.
    相关实验
    • Bcap-37和MDA-MB-435细胞的传代

      Bcap-37和MDA-MB-435细胞都是人乳腺癌细胞,培养液用DMEM或1640均可,小牛血清10%就足够,不过感觉435细胞用DMEM长得更旺一些。两种细胞都很好养,Bcap-37可称为是最漂亮的乳腺癌细胞,一个个成排列均匀的瓜子状,形态规则,长得也快,一般1:2传代后2-3天即可长满。435长的较慢,需4-5天。传代常规用0.25%的胰酶消化后用含血清的培养基终止消化,视消化程度而决定是否需要离心,传入新瓶加入培养液即可。需要注意的是传代时的密度,特别是435密度低时很难生长。一般生长

    • 人乳腺癌的裸鼠移植模型的制作

      乙酰肝素和巢蛋白组成的混合物,在4℃为液体,而在37℃则聚合形成一种凝胶。③裸鼠的选择Balb/c、 nu/nu雌性裸鼠 (SPF级),4-6周龄,体重18-22g,预实验选用Balb/c小鼠,用于mfp的解剖。 MDA-MB-435S细胞的成瘤情况 3、材料 常规器械:15号小圆刀、小刀柄、1ml,5ml空针、橡筋、定鼠板、钉子、止血钳、眼科剪、口罩帽子手套; 药品准备:安氟醚、NS、酒精、脱毛剂(硫化钠)、肾上腺素; 显微外科器械:8倍目视显微镜或16倍台式显微镜、显微手术器械(组织剪、持针

    • LightCycler通过实时荧光PCR技术进行DNA甲基化分析

      ”和“HRM基因扫描”软件模块分析的数据。(b)含100%甲基化和非甲基化质控品和50%、25%、10%、5%和1%的甲基化标准品的MGMT MS-HRM测定法。使用“Tm Calling”和“HRM基因扫描”软件模块分析的数据。 图2:(a)FANCF MS-HRM测定,显示稀释卵巢癌细胞株2008中存在DNA甲基化。(b)MGMT MS-HRM测定,显示乳腺癌细胞株MDA-MB435和HS578T中存在甲基化。 结果和讨论 针对两个基因的MS-HRM测定法都可检出非甲基化DNA背景下1%的甲基

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海沪震实业有限公司
    2026年04月28日询价
    ¥1680
    吉奥蓝图(广东)生命科学技术中心
    2025年04月09日询价
    ¥900
    上海泽叶生物科技有限公司
    2026年04月23日询价
    ¥900
    上海淳麦生物科技有限公司
    2025年07月11日询价
    ¥1150
    上海富雨生物科技有限公司
    2026年03月10日询价
    文献支持
    MDA-MB-435S细胞
    ¥1320